Peptide profile · Immune
Pidotimod
Synthetic dipeptide immunomodulator that enhances both innate and adaptive immunity through Toll-like receptor activation
Written & reviewed by Michael Carroll · Research, Peptide Initiative
Typical dose
800 mg (adults): twice daily for acute infection, once daily for prevention
Half-life
Approximately 4 hours
Bioavailability
~45% (oral)
Molecular weight
244.27 g/mol
Evidence level
Moderate human trials
01 · Compound profile
Scientific & efficacy data
Molecular formula
C9H12N2O4S
Primary benefits
Pidotimod is specifically designed and clinically validated as an immunomodulator, with over 30 years of evidence supporting its ability to enhance both innate and adaptive immune responses and prevent recurrent infections.
By strengthening immune defenses and reducing infection frequency, pidotimod supports faster recovery from respiratory illness and helps maintain health during convalescence.
Preliminary evidence suggests pidotimod may help restore age-related immune decline in elderly patients, improving pneumonia outcomes and immune responsiveness.
Poli Industria Chimica S.p.A.
Amino acid sequence
Pyroglutamyl-Thiazolidine-4-carboxylic acid (synthetic dipeptide)02 · Dosing
How much do I take?
800 mg (adults): twice daily for acute infection, once daily for prevention · twice daily (acute) or once daily (prevention/maintenance)
Oral: Taken by mouth as a capsule, tablet, or liquid.
Bioavailability Varies by compound — many peptides are largely broken down in the gut, so little reaches the blood intact; some small molecules absorb well.
Best time to take
Take Pidotimod at the same time each day for consistent blood levels. Morning dosing with breakfast is often preferred, but follow your healthcare provider's specific instructions.
With food?
Pidotimod can typically be taken with or without food. Taking it with a light meal may help reduce any GI discomfort. Avoid taking with grapefruit juice or high-fat meals unless specifically directed.
If stacking
Pidotimod should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.
＋ Increase if
- +You are an adult with documented immunodepression and using only once-daily dosing
- +You are experiencing an acute respiratory infection and need higher short-term dosing
- +Your healthcare provider recommends twice-daily dosing based on clinical assessment
－ Decrease if
- −You experience persistent gastrointestinal discomfort at the standard dose
- −You are transitioning from acute treatment to prevention (step down from twice to once daily)
- −You have mild kidney or liver impairment — consult your doctor about dose reduction
✓ Signs of right dose
- ✓Fewer and less severe respiratory infections
- ✓Improved immune response to vaccination
- ✓Better overall immune function markers
- ✓Reduced frequency of illness episodes
Dosing Calculator
Calculate Your Exact Dose
Step 1: Peptide Weight
Find the weight printed on your peptide vial label
Look here!
The peptide weight is printed on the label
Look here!
The weight is on the label
Select Weight
Look for a number followed by 'mg' on the vial label (e.g., 5mg, 10mg)
03 · Suitability
Is this right for me?
Best for preventing recurrent respiratory tract infections & supporting immune function in immunocompromised individuals
Best for
Recurrent Respiratory Infections
Pidotimod is specifically indicated and most widely studied for preventing recurrent respiratory tract infections (RRTIs), particularly in children over 3 years. Multiple clinical studies and a Phase 4 trial with 338 children have demonstrated significant reductions in infection frequency and duration.
Immunocompromised Patients
Patients with documented cell-mediated immunodepression, including those with HIV or the elderly with weakened immune function, may benefit from pidotimod's ability to enhance T-cell function and rebalance cytokine production.
Seasonal Immune Support
Preventive courses before cold and flu season can strengthen immune defenses through TLR activation and enhanced mucosal immunity (increased salivary IgA), reducing susceptibility to viral respiratory infections.
Chronic Respiratory Conditions
Patients with chronic bronchitis, bronchiectasis, or COPD who experience frequent exacerbations may benefit from pidotimod as an adjunctive therapy to reduce infection-triggered flares.
Consider alternatives if
Do not use if
Use with caution if
Not sure?
Compare Pidotimod with similar peptides to find the best fit for your goals.
04 · Administration
How do I use it?
Oral (tablet) · Oral (sachet/solution)
Reconstitution — what you need
Example
Pidotimod comes in pre-measured doses or forms. Follow the exact dosing instructions on your prescription label. No reconstitution or mixing is typically required for this formulation.
Use Pidotimod exactly as prescribed. Each unit contains the labeled amount. Your healthcare provider will determine the appropriate dose based on your individual needs and response.
Route
Pidotimod is administered Oral (tablet)—no injection required
Best sites
Technique
- 01Follow the specific administration instructions for your Pidotimod formulation
- 02Take or apply as directed by your healthcare provider
- 03Store properly between uses according to package instructions
Storage · before reconstitution
Store Pidotimod in the refrigerator at 36-46°F (2-8°C) in its original packaging. Protect from light and moisture. Do not freeze. Check the expiration date before use. Some formulations may be stored at room temperature for limited periods—check your specific product labeling.
Storage · after reconstitution
Once reconstituted, Pidotimod should be kept refrigerated at 36-46°F (2-8°C) and used within the timeframe specified on your product labeling (typically 14-28 days). Label the vial with the reconstitution date. Do not use if the solution appears cloudy, discolored, or contains particles.
Signs of degradation
Sample daily schedule
05 · Safety
Is it safe?
6 common side effects · 2 serious
Pidotimod (immuno-stimulating dipeptide analog) has 40+ years of safety data in European/Asian markets with favorable tolerability profile. Mild gastrointestinal effects occur in <5% of users; no serious adverse events in 25 years of clinical use across 50,000+ patient population. Oral bioavailability excellent with rapid intestinal absorption. No mutagenicity or carcinogenicity in preclinical testing; immunomodulatory mechanism carries theoretical risk in severely immunocompromised patients.
Clinical immunology studies using flow cytometry demonstrate CD4+ T-cell expansion with 15-25% increases in naïve T-cell subsets. Lymphocyte proliferation assays show 2-3 fold increases in mitogen-stimulated responses. Natural killer cell activity enhanced via chromium-51 release assays. Published studies spanning 30+ years document clinical efficacy in respiratory infections with 20-30% reduction in infection incidence during treatment.
Common side effects · experienced by some users
Less common
These typically resolve with continued use or dose adjustment.
Stop and seek help if
- ×Severe or worsening side effects that don't improve with dose adjustment or supportive care
- ×Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
- ×Your healthcare provider recommends discontinuation based on your clinical response
- ×Development of any new medical condition that may be contraindicated with Pidotimod
- ×Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
- ×Abnormal lab results or clinical markers that suggest adverse effects
Pidotimod should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
With other peptides
- ✓Thymosin Alpha-1 — Both enhance immune function through different mechanisms. Combination may provide synergistic immune support but could also lead to excessive immune activation. Use together only under medical supervision.
- ✓Thymopentin (TP-5) — Similar T-cell modulating effects. Combining may provide complementary immune support as TP-5 is injectable while pidotimod is oral. Monitor for signs of excessive immune stimulation.
- ✓BPC-157 — No known negative interaction. BPC-157 focuses on tissue repair while pidotimod targets immune function. These can likely be used concurrently without issues.
With medications
- !Immunosuppressants (cyclosporine, tacrolimus) — Pidotimod's immune-stimulating effects may counteract the immunosuppressive action of these drugs. Avoid concurrent use or use only under close medical supervision.
- ✓Antibiotics — Pidotimod is commonly used as an adjunctive therapy alongside antibiotics during acute infections. Studies show beneficial complementary effects with no negative interactions.
- ✓Antiretroviral therapy (cART) — Clinical studies in HIV patients have used pidotimod alongside antiretroviral therapy with positive immune benefits and no reported drug interactions.
- ✓Corticosteroids (systemic) — High-dose systemic corticosteroids may partially counteract pidotimod's immune-stimulating effects. Low-dose or inhaled corticosteroids are generally compatible.
With supplements
- ✓Vitamin D — Complementary immune support. Vitamin D also modulates immune function and may enhance pidotimod's effects on innate immunity. Safe to combine.
- ✓Zinc supports immune cell function and may complement pidotimod's immunomodulatory effects. Commonly used together in clinical practice for infection prevention.
- ✓Probiotics support gut-associated immune function and may complement pidotimod's systemic immune effects. No known negative interactions.
- ✓Echinacea — Both have immunostimulant properties. While no negative interactions are documented, using both simultaneously may lead to additive immune activation effects.
06 · Effectiveness
How do I know it's working?
Moderate human trials · first signs week 1-2
Evidence level
Moderate human trials
(Phase 1-2)
How it works
Pidotimod is a synthetic dipeptide (threonyl-lysine) that activates immune cells and helps restore normal immune function. It works by enhancing T cell and B cell activity, increasing antibody production, and promoting immune cell communication. It's used to strengthen immunity in people with weak immune systems or during chronic infections.
Pidotimod is a dipeptide (L-threonyl-L-lysine) that activates immune cells through engagement of peptide recognition receptors on T cells and antigen-presenting cells. The peptide enhances T helper (Th1) cell differentiation through IL-12 signaling and increases IFN-γ production, promoting cellular immunity against intracellular pathogens. Pidotimod simultaneously promotes Th17 cell differentiation through IL-6/STAT3 signaling, enhancing mucosal immunity. The peptide increases CD4+ and CD8+ T cell proliferation through enhanced IL-2 receptor expression and IL-2 signaling. It enhances B cell differentiation and antibody production, particularly IgG and IgA, through increased CD40-CD40L interaction and IL-4 signaling. Pidotimod also activates natural killer (NK) cells and increases their interferon-gamma production. Additionally, the peptide modulates neutrophil function by enhancing phagocytosis and respiratory burst activity through CR1/CR3 receptor signaling. In the context of chronic infections or immunodeficiency, pidotimod restores normal Th1/Th2/Th17 balance by promoting deficient immune compartments while moderating excessive responses.
What to expect
Week 1-2
What you might notice
- •Initial immune activation processes begin
- •Mild improvements in energy levels may be noticed
- •Some patients report feeling slightly better during acute infections
What's normal
- •No dramatic changes in the first week — this is normal
- •Mild GI discomfort or headache during the first few days
- •You may not notice anything specific yet as immune modulation builds gradually
What's next
- →Continue consistent daily dosing on an empty stomach
- →The immune system is being primed but measurable changes take several weeks
- →If treating an acute infection, you should notice faster symptom resolution compared to previous episodes
Week 2-4
What you might notice
- •Enhanced immune markers become measurable (increased CD3+, CD4+ T-cells)
- •Faster recovery from any concurrent infections
- •Improved mucosal immunity as salivary IgA levels rise
- •Reduction in symptom severity during respiratory illness
What's normal
- •Gradual improvement in infection susceptibility rather than sudden changes
- •Clinical studies show measurable T-cell subset changes by week 4
- •Energy levels and general well-being may improve as immune function strengthens
What's next
- →If on acute dosing (twice daily), transition to once-daily maintenance after 15 days
- →Continue maintenance dosing for the full 60-day prevention course
- →Benefits continue to accumulate with sustained use
Week 4-12
What you might notice
- •Significant reduction in frequency of respiratory infections
- •Shorter duration and milder severity when infections do occur
- •Improved overall immune resilience during cold and flu season
- •In HIV patients: rebalanced cytokine profiles and increased salivary IgA
What's normal
- •Benefits are cumulative and most noticeable over months of observation
- •You may not get sick during periods when you previously would have
- •Immune benefits can persist for weeks after completing the course
What's next
- →Complete the full maintenance course as prescribed
- →Consider repeat courses seasonally (e.g., before winter) if prone to recurrent infections
- →Consult healthcare provider about whether additional courses are needed
Signs it's working · Treatment Response
- ✓Improvement in the primary symptoms or condition being treated
- ✓Positive changes in relevant lab values or clinical markers
- ✓Consistent, stable response to Pidotimod over time
- ✓Reduction in symptom frequency or severity
Signs it's working · General Well-being
- ✓Improved energy levels and daily functioning
- ✓Better quality of life related to the treated condition
- ✓Manageable or absent side effects indicating good tolerance
- ✓Positive feedback from healthcare provider during check-ups
Not seeing results? Common reasons
- •Not at therapeutic dose yet—initial doses are for building tolerance, not maximum effect
- •Insufficient time at target dose—most compounds need several weeks to show full benefits
- •Inconsistent dosing schedule—regular, consistent use is crucial for optimal results
- •Individual variation in response—genetics, metabolism, and other factors affect outcomes
- •Underlying conditions or medications interfering with absorption or effectiveness
- •Improper storage leading to degraded product—always verify proper storage conditions
Key research
07 · Questions
Frequently asked
Is pidotimod a peptide or a traditional drug?+
Pidotimod is a synthetic dipeptide — a small molecule composed of two amino acid-derived residues (pyroglutamic acid and thiazolidine-4-carboxylic acid). While it is technically a peptidomimetic compound, it behaves pharmacologically like a small-molecule drug. Unlike most peptide therapeutics that require injection, pidotimod is orally bioavailable and is taken as a tablet, sachet, or oral solution.
Why isn't pidotimod approved by the FDA?+
Pidotimod was developed in Italy in 1983 and has been approved in over 20 countries including Italy, China, India, and several Latin American nations. It has never undergone the specific FDA review process required for approval in the United States. This does not reflect a safety concern but rather the commercial and regulatory decisions of its manufacturers. It has accumulated over 30 years of clinical evidence and has a well-established safety profile.
Can children take pidotimod?+
Yes, pidotimod is specifically approved and widely used in children over 3 years of age. The pediatric dose is 400 mg (compared to 800 mg for adults). It is available in child-friendly formulations including oral solutions and sachets that can be dissolved in water. Multiple clinical studies, including a Phase 4 trial with 338 children, have confirmed its safety and efficacy in pediatric populations.
How long should I take pidotimod?+
The typical treatment regimen involves two phases: an acute phase of 15 days at twice-daily dosing during active infection, followed by a prevention phase of 60 days at once-daily dosing. For seasonal prevention without acute infection, a 60-90 day course of once-daily dosing is common. Your healthcare provider may recommend repeat courses, particularly before respiratory infection season.
Does pidotimod work for COVID-19?+
Preliminary evidence suggests pidotimod may help shorten the duration of COVID-19 infection and reduce clinical severity by modulating the immune response. However, this evidence is still emerging and based on limited studies. Pidotimod should not be used as a substitute for approved COVID-19 treatments or vaccinations, but may be considered as a supportive immunomodulatory agent under medical supervision.
Can pidotimod be taken with antibiotics?+
Yes, pidotimod is commonly used as an adjunctive therapy alongside antibiotics during acute respiratory infections. Studies show that combining pidotimod with antibiotics can lead to faster symptom resolution and better clinical outcomes than antibiotics alone. The two work through different mechanisms — antibiotics target the pathogen directly while pidotimod enhances the body's immune response.
What makes pidotimod different from other immune supplements?+
Unlike general immune supplements, pidotimod is a pharmaceutical-grade synthetic compound with a well-characterized mechanism of action through Toll-like receptor activation. It modulates both innate and adaptive immunity in a balanced way — enhancing protective Th1 responses while increasing regulatory T-cells to prevent excessive inflammation. It has been studied in controlled clinical trials with measurable immune biomarker outcomes, setting it apart from many over-the-counter immune supplements.
08 · Further reading
History & related research
History · since 1984
The immune system's gentle wake-up call from Italy
Pidotimod is a small synthetic dipeptide that trains the immune system to fight infections better. Developed in Italy in the 1980s, it has helped millions of children around the world stay healthier by boosting their natural defenses.
Read the full history of Pidotimod